bioAffinity Technologies (NASDAQ:BIAF) Trading Down 2% – Should You Sell?

bioAffinity Technologies, Inc. (NASDAQ:BIAF)’s stock price fell 2% during trading on Monday . The stock traded as low as $0.88 and last traded at $0.97. 173,044 shares were traded during mid-day trading, an increase of 23% from the average session volume of 140,314 shares. The stock had previously closed at $0.99.

bioAffinity Technologies Price Performance

The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.73. The stock has a market cap of $14.81 million, a PE ratio of -1.16 and a beta of 2.85.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is currently owned by institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.